Skip to main navigation
logo
F-star Therapeutics Logo F-star Therapeutics Logo

Investor Relations

  • Home
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Media Contact
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials
    • SEC Filings
    • Quarterly Results
  • Governance
    • Documents & Charters
    • Board of Directors
    • Leadership
    • Committee Composition
  • Publications
  • IR Resources
    • Investor Contact
    • Email Alerts

Press Releases

Apr 10, 2021
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
PDF Version
Apr 01, 2021
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
PDF Version
Mar 29, 2021
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
PDF Version
Mar 16, 2021
F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021
PDF Version
Mar 04, 2021
F-star Therapeutics to Present at Upcoming Investor Conferences
PDF Version
Jan 20, 2021
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
PDF Version
Jan 06, 2021
F-star Therapeutics to Participate in Upcoming Conferences
PDF Version
Jan 04, 2021
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
PDF Version

Shareholder Tools

  • Print Page
  • RSS
  • Contact IR

© 2021 F-star Therapeutics, Inc.

Footer Legal

  • Disclaimer
  • Privacy Policy
  • Cookie Policy
  • Careers
  • Contact Us
  • Sitemap

Footer Social

  • Get in touch